Glenmark Pharmaceuticals receives ANDA approval for Frovatriptan Succinate Tablets

14 Mar 2016 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg, the therapeutic equivalent to the reference listed drug product, Frova Tablets, 2.5 mg, of Endo Pharmaceuticals, Inc.

According to IMS Health sales data for the 12 month period ending January 2016, the Frova Market achieved annual sales of approximately $87.8 million.

Glenmark’s current portfolio consists of 108 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1237.10 11.85 (0.97%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.